- Home
- NMM vs VIR Comparison
NMM vs VIR Comparison
Compare NMM & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMM
- VIR
- Stock Information
- Founded
- NMM 2007
- VIR 2016
- Country
- NMM Greece
- VIR United States
- Employees
- NMM N/A
- VIR N/A
- Industry
- NMM Marine Transportation
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- NMM Consumer Discretionary
- VIR Health Care
- Exchange
- NMM Nasdaq
- VIR Nasdaq
- Market Cap
- NMM 959.8M
- VIR 844.9M
- IPO Year
- NMM 2007
- VIR 2019
- Fundamental
- Price
- NMM $39.20
- VIR $4.94
- Analyst Decision
- NMM Strong Buy
- VIR Strong Buy
- Analyst Count
- NMM 1
- VIR 7
- Target Price
- NMM $80.00
- VIR $32.86
- AVG Volume (30 Days)
- NMM 83.5K
- VIR 1.6M
- Earning Date
- NMM 05-07-2025
- VIR 05-07-2025
- Dividend Yield
- NMM 0.51%
- VIR N/A
- EPS Growth
- NMM N/A
- VIR N/A
- EPS
- NMM 11.23
- VIR N/A
- Revenue
- NMM $1,319,623,000.00
- VIR $20,861,000.00
- Revenue This Year
- NMM N/A
- VIR N/A
- Revenue Next Year
- NMM $7.93
- VIR $15.32
- P/E Ratio
- NMM $3.49
- VIR N/A
- Revenue Growth
- NMM 0.28
- VIR N/A
- 52 Week Low
- NMM $28.37
- VIR $4.32
- 52 Week High
- NMM $65.89
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- NMM 58.59
- VIR 45.01
- Support Level
- NMM $37.81
- VIR $4.37
- Resistance Level
- NMM $39.90
- VIR $5.24
- Average True Range (ATR)
- NMM 1.15
- VIR 0.32
- MACD
- NMM -0.07
- VIR 0.07
- Stochastic Oscillator
- NMM 37.77
- VIR 49.60
About NMM Navios Maritime Partners LP Common Units Representing Limited Partner Interests
Navios Maritime Partners LP is a seaborne shipping company. It owns and operates dry cargo and container vessels with the primary long-term and staggered expiration charters. The firm's fleet consists of Ultra- Handymax, Panamax, Capsize, and Container vessels and categorized in Drybulk and Container vessels. It earns revenue through the chartering of vessels and voyage contracts. Geographically, it generates majority revenue from Asia.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.